Ark Surgical
Ark Surgical protects patients from cancer spread risk during minimally invasive surgery and helps hospitals reduce liability with FDA-cleared safety tools
Problem & solution
Many minimally invasive surgeries require cutting large tissue through small incisions. The risk is hidden cancer spread if tissue is not contained. Ark’s FDA-cleared, single-use LapBox isolates tissue during removal, helping surgeons preserve robotic surgery while protecting patients and hospitals.
Primary customers & users
Hospitals and ASCs buy LapBox through GYN, GYN Oncology, VAC, purchasing, risk management, and patient safety teams. Primary users are surgeons performing robotic and minimally invasive large-tissue removal, mainly GYN Oncology, MIGS, and high-volume GYN surgeons.
Differentiation
LapBox is the only FDA-cleared containment platform with a double safety system and double approval - for both manual and power morcellation. It replaces older single-wall bags with a purpose-built, best-in-class safety tool designed to reduce leakage, rupture risk, and hospital liability.
Current traction
Ark has FDA clearance for both manual and power morcellation. LapBox is in use in leading U.S. hospitals, including MedStar in Washington, DC, Ochsner in New Orleans, and Woman’s Hospital in Baton Rouge. Ark has completed 200+ clinical cases, received hospital reorders, and is expanding from Louisiana into Texas and Florida. We also have active evaluations in Tier 1 U.S. hospital and an approved clinical trial in major university starting 2027.
How Summit participants can help
Introductions to leading hospitals and high-level GYN and GYN Oncology surgeons locally, in Texas, and in Florida would be highly valuable. We are also seeking support in closing our Series A through family offices, angel investors, and small VCs. This will help accelerate U.S. sales team expansion and hospital adoption.